Tokyo, Japan and Mont-Saint-Guibert, Belgium – BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Stemcyte First Biotech to Receive FDA Approval of a Cord Blood Derived Cellular Therapeutic
FDA Grants Approval to StemCyte for REGENECYTE™ Cord Blood Cell Therapy
StemCyte Inc., a subsidiary of StemCyte International Ltd., has achieved a landmark in regenerative medicine with the U.S. Food and Drug Administration’s (FDA) approval of its Biologics License Application (BLA) for REGENECYTE™. Announced on November 22, 2024, this cord blood derived cellular therapeutic is designed to treat patients with blood and immune system disorders, making StemCyte the first commercial biotech company to receive a biologics license for a cord blood stem cell therapy. [Read more…]
LifeCell International, India’s Largest Cord Blood Bank
LifeCell is India’s largest cord blood bank, offering stem cell banking services and diagnostic testing. Established in 2004, its BabyCord program is one of the largest cord blood banking programs in the region, with 50,000+ parents preserving newborn stem cells each year and 375,000 units cryopreserved.
I had the privilege of interviewing Mr. Mayur Abhaya Srisrimal, Chief Executive Officer and Managing Director of LifeCell. Mr. Abhaya has led LifeCell since 2008 and been instrumental in expanding its stem cell storage services across India with its BabyCord program. Under his leadership, LifeCell also raised growth capital from Helion Ventures and extended its preventive diagnostic services by launching BabyShield, a program targeted at reducing the infant mortality ratio. [Read more…]
104 Current & Future Uses of Umbilical Cord Stem Cells (Today in 2025)
Umbilical cord stem cells are present within the cord that connects a newborn to its mother and uses of these birth cells include treating cancers, diseases, injuries, and more. Umbilical cord blood contains hematopoietic stem cells (HSCs), which are multipotent stem cells that can give rise to other blood and immune system cells.
Stem cells can also be collected from a newborn’s:
- Umbilical cord tissue (Wharton’s jelly)
- Placenta
- Amnion
Most commonly, hematopoietic stem cells (HSCs) from cord blood are used to treat blood cancers, such as leukemia. When compared to hematopoietic stem cells from genetically matched bone marrow donor, cord blood HSCs may provide some medical advantages, including fewer immune system complications, such as graft-versus-host disease (GvHD).
In recent years, regenerative medicine has continued to increase the list of medical uses for stem cells from umbilical cord. Find out more about current and future uses of umbilical cord stem cells below.
In this article:
Cord Blood Market Intelligence: A Region-By-Region Analysis
The practice of cord blood banking, where stem cells from a newborn’s umbilical cord are preserved for potential future medical use, has gained significant traction worldwide. However, adoption rates, regulatory frameworks, and public awareness vary significantly across geographic regions. In some areas, robust public and private banking systems drive widespread participation, while in others, the practice remains nascent, shaped by cultural attitudes, healthcare infrastructure, and policy.
In addition to being complex industry, it is also a recent industry. It was not until 1974 that it was first proposed that progenitor cells were present in human cord blood and 1983 that umbilical cord blood was proposed as an alternative source of stem cells for transplant. In 1988, the first successful cord blood transplant occurred, but it was not until 1995 that the first private cord blood bank began operations.
Since 1988, stem cells from umbilical blood have been used in more than 40,000 transplants worldwide.
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 62
- Next Page »